The company said EBITDA for the 3 months ended September 30, 2024 rose to $393.8 million from $346.8 million a year earlier, and its EBITDA margin was 54.3% compared with 51.2% a year earlier. EBITDA is a non-GAAP measure.

10-QQuarterly reportFiled Oct 30, 2024Period of report Sep 30, 2024Summary published (UTC) Oct 23, 2026

Key points

AI summary

The company said EBITDA for the 3 months ended September 30, 2024 rose to $393.8 million from $346.8 million a year earlier, and its EBITDA margin was 54.3% compared with 51.2% a year earlier. EBITDA is a non-GAAP measure.
The company said its net income margin for the 9 months ended 2024 was 34.8% compared with 22.0% a year earlier, and cited net gains from the settlement of retained interests related to the prior sales of its healthcare business in 2016 and its specialized markets business in 2022 as factors behind the increase. Investment gain was $102.4 million.
The company said Insurance segment revenue excluding its recent acquisition of Rocket rose $47.1 million, or 7.0%, in Q3. It said underwriting revenue increased $31.8 million (6.7%) and claims revenue increased $15.3 million (7.6%).
The company said net cash provided by operating activities for the 9 months ended 2024 was $888.6 million. Financing cash outflows over the same period included $750.0 million for accelerated share repurchase programs and $166.6 million in dividend payments.

Key figures

Quarter ended September 30, 2024

Revenue: $725M
Operating income: $312M
Net income: $220M
EPS: $1.54
Operating cash flow: $296M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q3 2024 EBITDA and EBITDA Margin

The company said EBITDA for the 3 months ended September 30, 2024 rose to $393.8 million from $346.8 million a year earlier, and its EBITDA margin was 54.3% compared with 51.2% a year earlier. EBITDA is a non-GAAP measure.

Source · Based on the MD&A text of the filing

9-Month Net Income Margin and Investment Gain

The company said its net income margin for the 9 months ended 2024 was 34.8% compared with 22.0% a year earlier, and cited net gains from the settlement of retained interests related to the prior sales of its healthcare business in 2016 and its specialized markets business in 2022 as factors behind the increase. Investment gain was $102.4 million.

Source · Based on the MD&A text of the filing

Q3 Insurance Revenue Growth Explained

The company said Insurance segment revenue excluding its recent acquisition of Rocket rose $47.1 million, or 7.0%, in Q3. It said underwriting revenue increased $31.8 million (6.7%) and claims revenue increased $15.3 million (7.6%).

Source · Based on the MD&A text of the filing

9-Month Cash Flow and Share Repurchases

The company said net cash provided by operating activities for the 9 months ended 2024 was $888.6 million. Financing cash outflows over the same period included $750.0 million for accelerated share repurchase programs and $166.6 million in dividend payments.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.